{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T20:50:47Z","timestamp":1781383847156,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1245\/s10434-021-09943-7","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T18:38:42Z","timestamp":1618857522000},"page":"6060-6068","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Palpable Adenopathy Does Not Indicate High-Volume Axillary Nodal Disease in Hormone Receptor-Positive Breast Cancer"],"prefix":"10.1245","volume":"28","author":[{"given":"Angelena","family":"Crown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"issue":"12","key":"9943_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol"},{"issue":"6","key":"9943_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375.","journal-title":"JAMA"},{"issue":"10","key":"9943_CR3","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA"},{"issue":"14","key":"9943_CR4","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA"},{"issue":"10","key":"9943_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol. 2016;34(10):1072\u20138.","journal-title":"J Clin Oncol"},{"issue":"11","key":"9943_CR6","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study. Ann Surg Oncol. 2016;23(11):3467\u201374.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"9943_CR7","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1245\/s10434-017-5898-z","volume":"24","author":"OA Petruolo","year":"2017","unstructured":"Petruolo OA, Pilewskie M, Patil S, et al. Standard pathologic features can be used to identify a subset of estrogen receptor-positive, HER2 negative patients likely to benefit from neoadjuvant chemotherapy. Ann Surg Oncol. 2017;24(9):2556\u201362.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"9943_CR8","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1245\/s10434-020-08888-7","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Sevilimedu V, Fornier M, Jhaveri K, Morrow M, Pilewskie ML. How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery? Ann Surg Oncol. 2020;27(12):4702\u201310.","journal-title":"Ann Surg Oncol"},{"key":"9943_CR9","volume-title":"AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th edn. NewYork: Springer; 2010.","edition":"7"},{"issue":"16","key":"9943_CR10","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond ME, Hayes DF, Dowsett M, et al. American society of clinical oncology\/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784\u201395.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9943_CR11","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000002354","volume":"266","author":"M Morrow","year":"2017","unstructured":"Morrow M, Van Zee KJ, Patil S, et al. Axillary dissection and nodal irradiation can be avoided for most node-positive Z0011-eligible breast cancers: a prospective validation study of 793 patients. Ann Surg. 2017;266(3):457\u201362.","journal-title":"Ann Surg"},{"issue":"7","key":"9943_CR12","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15(7):2483\u201393.","journal-title":"J Clin Oncol."},{"key":"9943_CR13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09228-5","author":"S Angarita","year":"2020","unstructured":"Angarita S, Ye L, Runger D, et al. Assessing the burden of nodal disease for breast cancer patients with clinically positive nodes: hope for more limited axillary surgery. Ann Surg Oncol. 2020. https:\/\/doi.org\/10.1245\/s10434-020-09228-5.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"9943_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00000658-199904000-00013","volume":"229","author":"KU Chu","year":"1999","unstructured":"Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg. 1999;229(4):536\u201341.","journal-title":"Ann Surg"},{"issue":"6","key":"9943_CR15","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1200\/JCO.1999.17.6.1720","volume":"17","author":"C Reynolds","year":"1999","unstructured":"Reynolds C, Mick R, Donohue JH, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol. 1999;17(6):1720\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"9943_CR16","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/1097-0142(20000801)89:3<574::AID-CNCR12>3.0.CO;2-Y","volume":"89","author":"RR Turner","year":"2000","unstructured":"Turner RR, Chu KU, Qi K, et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer. 2000;89(3):574\u201381.","journal-title":"Cancer"},{"issue":"2","key":"9943_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10434-001-0145-y","volume":"8","author":"MR Weiser","year":"2001","unstructured":"Weiser MR, Montgomery LL, Tan LK, et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol. 2001;8(2):145\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"9943_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1001\/archsurg.136.5.563","volume":"136","author":"SL Wong","year":"2001","unstructured":"Wong SL, Edwards MJ, Chao C, et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg. 2001;136(5):563\u20138.","journal-title":"Arch Surg"},{"issue":"6","key":"9943_CR19","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/1097-0142(20010915)92:6<1378::AID-CNCR1460>3.0.CO;2-Y","volume":"92","author":"G Viale","year":"2001","unstructured":"Viale G, Maiorano E, Mazzarol G, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92(6):1378\u201384.","journal-title":"Cancer"},{"issue":"3","key":"9943_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0002-9610(02)00794-8","volume":"183","author":"U Sachdev","year":"2002","unstructured":"Sachdev U, Murphy K, Derzie A, Jaffer S, Bleiweiss IJ, Brower S. Predictors of nonsentinel lymph node metastasis in breast cancer patients. Am J Surg. 2002;183(3):213\u20137.","journal-title":"Am J Surg"},{"issue":"10","key":"9943_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1245\/ASO.2003.03.015","volume":"10","author":"KJ Van Zee","year":"2003","unstructured":"Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140\u201351.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"9943_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jamcollsurg.2015.11.013","volume":"222","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M. Is preoperative axillary imaging beneficial in identifying clinically node-negative patients requiring axillary lymph node dissection? J Am Coll Surg. 2016;222(2):138\u201345.","journal-title":"J Am Coll Surg"},{"issue":"4","key":"9943_CR23","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1245\/s10434-015-4944-y","volume":"23","author":"M Pilewskie","year":"2016","unstructured":"Pilewskie M, Mautner SK, Stempel M, Eaton A, Morrow M. Does a positive axillary lymph node needle biopsy result predict the need for an axillary lymph node dissection in clinically node-negative breast cancer patients in the ACOSOG Z0011 era? Ann Surg Oncol. 2016;23(4):1123\u20138.","journal-title":"Ann Surg Oncol"},{"key":"9943_CR24","unstructured":"National Comprehensive Cancer Network. Breast Cancer (V 6.2020). Plymouth Meeting, PA: National Comprehensive Cancer Network; 2020."},{"issue":"11","key":"9943_CR25","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.1245\/s10434-020-08650-z","volume":"27","author":"G Montagna","year":"2020","unstructured":"Montagna G, Mamtani A, Knezevic A, Brogi E, Barrio AV, Morrow M. Selecting node-positive patients for axillary downstaging with neoadjuvant chemotherapy. Ann Surg Oncol. 2020;27(11):4515\u201322.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"9943_CR26","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV, et al. Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg. 2014;260(4):608\u201316.","journal-title":"Ann Surg"},{"issue":"7","key":"9943_CR27","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"22","key":"9943_CR28","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"9943_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1245\/s10434-020-08593-5","volume":"28","author":"O Petruolo","year":"2021","unstructured":"Petruolo O, Sevilimedu V, Montagna G, Le T, Morrow M, Barrio AV. How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery? Ann Surg Oncol. 2021;28(1):287\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"9943_CR30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-018-4964-y","volume":"173","author":"H Iwata","year":"2019","unstructured":"Iwata H, Masuda N, Yamamoto Y, et al. Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. Breast Cancer Res Treat. 2019;173(1):123\u201333.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9943_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1245\/s10434-018-07107-8","volume":"26","author":"AM Pease","year":"2019","unstructured":"Pease AM, Riba LA, Gruner RA, Tung NM, James TA. Oncotype DX\u00ae recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"9943_CR32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10549-015-3613-y","volume":"154","author":"DA Yardley","year":"2015","unstructured":"Yardley DA, Peacock NW, Shastry M, et al. A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score. Breast Cancer Res Treat. 2015;154(2):299\u2013308.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"9943_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s10549-006-9366-x","volume":"103","author":"L Mina","year":"2007","unstructured":"Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat. 2007;103(2):197\u2013208.","journal-title":"Breast Cancer Res Treat"},{"issue":"2\u20133","key":"9943_CR34","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3233\/BD-150199","volume":"36","author":"A Soran","year":"2016","unstructured":"Soran A, Bhargava R, Johnson R, et al. The impact of Oncotype DX\u00ae recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer. Breast Dis. 2016;36(2\u20133):65\u201371.","journal-title":"Breast Dis"},{"issue":"1","key":"9943_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","volume":"11","author":"KS Albain","year":"2010","unstructured":"Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55\u201365.","journal-title":"Lancet Oncol"},{"issue":"20","key":"9943_CR36","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1200\/JCO.2015.63.5383","volume":"34","author":"O Gluz","year":"2016","unstructured":"Gluz O, Nitz UA, Christgen M, et al. West german study group phase III PlanB trial: first prospective outcome data for the 21-Gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment. J Clin Oncol. 2016;34(20):2341\u20139.","journal-title":"J Clin Oncol"},{"key":"9943_CR37","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41523-017-0033-7","volume":"3","author":"SM Stemmer","year":"2017","unstructured":"Stemmer SM, Steiner M, Rizel S, et al. Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry. NPJ Breast Cancer. 2017;3:32.","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"9943_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1245\/s10434-018-7068-3","volume":"26","author":"M Wang","year":"2019","unstructured":"Wang M, Wu K, Zhang P, Zhang M, Ding A, Chen H. The prognostic significance of the oncotype DX recurrence score inT1-2N1M0 estrogen receptor-positive HER negative breast cancer based on the prognostic stage in the updated AJCC 8th edition. J Ann Surg Oncol. 2019;26(5):1227\u201335.","journal-title":"J Ann Surg Oncol"},{"issue":"3","key":"9943_CR39","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","volume":"165","author":"U Nitz","year":"2017","unstructured":"Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017;165(3):573\u201383.","journal-title":"Breast Cancer Res Treat"},{"key":"9943_CR40","doi-asserted-by":"crossref","unstructured":"Hortobagyi G, Shak S, Sledge G, et al. Abstract P3-11-02: Breast cancer-specific mortality (BCSM) in patients (pts) with node-negative (N0) and node-positive (N+) breast cancer (BC) guided by the 21-gene assay: A SEER-genomic population-based study. Cancer Research. 2019;79(4 Suppl):P3-11-02-P13-11-02.","DOI":"10.1158\/1538-7445.SABCS18-P3-11-02"},{"key":"9943_CR41","unstructured":"Kalinsky K, Barlow WE, Meric-Bernstam F, et al. SWOG S1007: adjuvant trial randomized ER+ patients who had a recurrence score <25 and 1-3 positive nodes to endocrine therapy (ET) versus ET + chemotherapy. In: Virtual San Antonio Breast Cancer Symposium; 8\u201311 December 2020."},{"issue":"1","key":"9943_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.22237\/jmasm\/1304222940","volume":"10","author":"GP Brooks","year":"2011","unstructured":"Brooks GP, Johanson GA. Sample size considerations for multiple comparison procedures in ANOVA. J Mod Appl Stat Methods. 2011;10(1):97\u2013109.","journal-title":"J Mod Appl Stat Methods"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-09943-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-09943-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T10:07:05Z","timestamp":1632478025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-09943-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["9943"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-09943-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]},"assertion":[{"value":"22 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Monica Morrow has received honoraria from Genomic Health. All other \nauthors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}